Phase II and III clinical studies proved IL-17 inhibitors as safe and efficient for the treatment of psoriasis, rheumatoid arthritis, and inflammatory bowel disease [198,199,200,201]. This evidence concerns the gene IL17A and inflammatory bowel disease.